Silence Therapeutics plc (SLN)
Nasdaq · Healthcare · Biotechnology
$10.14−4.70%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $630M
- 52-week range
- $4.19 – $17.58
- 52-week change
- +105.01%
- EPS (trailing)
- −$1.29
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $559K (−98.71%)
- Net income
- −$88.6M
- Operating margin
- −16292.8%
- Diluted EPS
- −$0.63
- Free cash flow
- −$62.3M
From the company’s annual report on SEC EDGAR.
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Headquarters: London, United Kingdom · 88 employees · silence-therapeutics.com